CAC
ABUS icon

Cowen and Company’s Arbutus Biopharma ABUS Stock Holding History

Cowen and Company’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-37,500
Closed -$79K – 583
2021
Q1 		$79K Buy
+37,500
New +$145K 0.01% 342
2020
Q4 		– Sell
-25,000
Closed -$58K – 394
2020
Q3 		$58K Buy
+25,000
New +$76K 0.01% 292

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FCM
FourWorld Capital Management New York $196M AUM 42.39% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Cowen and Company's ABUS Position: Q3 2024 in Review

Cowen and Company sold out of Arbutus Biopharma (ABUS) in Q3 2024, closing a stake of 20,000 shares — an estimated $61.8K sold.

Cowen and Company first reported a position in ABUS in Q4 2019 and held it in 11 quarters. The position peaked at $7.88M in Q2 2020. 144 funds tracked by Wall St. Rank hold ABUS as of Q3 2024.

  • Cowen and Company reported no remaining Arbutus Biopharma position as of Q3 2024 after selling out during the quarter.
  • Cowen and Company sold 20,000 Arbutus Biopharma shares in Q3 2024, an estimated $61.8K.
  • Cowen and Company first reported a position in Arbutus Biopharma in Q4 2019 and held it in 11 quarters.
  • Cowen and Company's Arbutus Biopharma position peaked at $7.88M in Q2 2020.
  • 144 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q3 2024.

Based on Cowen and Company's 13F filing for Q3 2024, filed 12 Nov 2024.